The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer

Weber, Manuel; Binse, Ina; Nagarajah, James; Bockisch, Andreas; Herrmann, Ken; Jentzen, Walter

doi:10.23736/s1824-4785.19.03201-1

Cited by 22 publications

(8 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A uniform clinical protocol for 124 I PET/CT imaging, image analysis, and quantification is yet to be established. Despite its technical advantages, and supporting data (17,39,40,(42)(43)(44)(45)(46), 124 I PET/CT use is still restricted to clinical trial settings.…”

Section: Current Standards: Clinical and Technical Considerations In Rai Imagingmentioning

confidence: 99%

A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer

Güleç

Ahuja

Avram

et al. 2021

Thyroid

View full text Add to dashboard Cite

Background: The American Thyroid Association (ATA), the European Association of Nuclear Medicine, the European Thyroid Association, and the Society of Nuclear Medicine and Molecular Imaging have established an intersocietal working group to address the current controversies and evolving concepts in thyroid cancer management and therapy. The working group annually identifies topics that may significantly impact clinical practice and publishes expert opinion articles reflecting intersocietal collaboration, consensus, and suggestions for further research to address these important management issues. Summary: In 2019, the intersocietal working group identified the following topics for review and interdisciplinary discussion: (i) perioperative risk stratification, (ii) the role of diagnostic radioactive iodine (RAI) imaging in initial staging, and (iii) indicators of response to RAI therapy. Conclusions: The intersocietal working group agreed that (i) initial patient management decisions should be guided by perioperative risk stratification that should include the eighth edition American Joint Committee on Cancer staging system to predict disease specific mortality, the modified 2009 ATA risk stratification system to

show abstract

Section: Current Standards: Clinical and Technical Considerations In Rai Imagingmentioning

confidence: 99%

A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer

Güleç

Ahuja

Avram

et al. 2021

Thyroid

View full text Add to dashboard Cite

show abstract

“…Our results support the examination of patients with differentiated thyroid carcinoma after thyroidectomy with any of the two-hybrid imaging modalities, 124 I-PET/CT or 124 I-PET/MR. The results of this study also imply that repeated exams of individual patients under therapy or for lesion dosimetry planning [6,27,33,34] should-whenever possible-be conducted with the same modality and, furthermore, on the same system to reduce methodological differences as far as possible [27]. Changes in individual lesion activity measured by PET ideally should be due to therapeutic effects only, and not due to changes in the hybrid imaging modality, methodology, imaging protocol, PET recon parameters, and/or AC method.…”

Section: Discussionmentioning

confidence: 52%

Intra-Individual Comparison of 124I-PET/CT and 124I-PET/MR Hybrid Imaging of Patients with Resected Differentiated Thyroid Carcinoma: Aspects of Attenuation Correction

Grafe

Lindemann

Weber

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Background: This study evaluates the quantitative differences between 124-iodine (I) positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MR) in patients with resected differentiated thyroid carcinoma (DTC). Methods: N = 43 124I PET/CT and PET/MR exams were included. CT-based attenuation correction (AC) in PET/CT and MR-based AC in PET/MR with bone atlas were compared concerning bone AC in the head-neck region. AC-map artifacts (e.g., dentures) were noted. Standardized uptake values (SUV) were measured in lesions in each PET data reconstruction. Relative differences in SUVmean were calculated between PET/CT and PET/MR with bone atlas. Results: Overall, n = 111 124I-avid lesions were detected in all PET/CT, while n = 132 lesions were detected in PET/MR. The median in SUVmean for n = 98 congruent lesions measured in PET/CT was 12.3. In PET/MR, the median in SUVmean was 16.6 with bone in MR-based AC. Conclusions: 124I-PET/CT and 124I-PET/MR hybrid imaging of patients with DTC after thyroidectomy provides overall comparable quantitative results in a clinical setting despite different patient positioning and AC methods. The overall number of detected 124I-avid lesions was higher for PET/MR compared to PET/CT. The measured average SUVmean values for congruent lesions were higher for PET/MR.

show abstract

“…Pre-therapeutic dosimetry of tumor lesions and organs-at-risk enable personalized dosimetry with the goal of maximizing tumor response, while keeping toxicity levels acceptable. The potential of personalized dosimetry for 131 I therapy has previously been described in the context of differentiated thyroid cancer (25,35,36) but data on pheochromocytoma are scarce (18,34,37). In our cohort 86% of patients with known MMP were MIBG-positive.…”

Section: Discussionmentioning

confidence: 78%

Diagnostic Performance of ¹²⁴I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction: 123/131 I-MIBG scintigraphy has shown a high specificity for imaging pheochromocytoma and paraganglioma however with low sensitivity due to low spatial resolution. 124 I-MIBG PET may overcome this limitation to improve the staging of patients with (suspected) pheochromocytoma. Methods: We analyzed the sensitivity, specificity, positive and negative predictive values (PPV, NPV) of 124 I-MIBG PET in 43 consecutive patients with suspected (recurrence of) pheochromocytoma using histopathological (n=25) and clinical validation (n=18) as standard of truth. Furthermore, we compared 124 I-MIBG PET versus contrast enhanced CT (CE-CT) per-patient and per-lesion detection rate of 124 I-MIBG PET in 13 additional patients with known metastatic malignant pheochromocytoma (MMP). Results: 124 I-MIBG PET/CT was positive in 19/43 (44%) patients with suspected pheochromocytoma. Presence of pheochromocytoma was confirmed in 22/43 (51%). 124 I-MIBG PET/CT sensitivity, specificity, PPV, NPV were 86%, 100%, 100%, 88%, respectively. 124 I-MIBG PET was positive in 11/13 (85%) MMP patients. Combined 124 I-MIBG PET and CE-CT detected 173 lesions, of which 166 (96%) and 118 (68%) were visible on 124 I-MIBG PET and CE-CT, respectively. Discussion: 124 I-MIBG PET detects pheochromocytoma with high accuracy at initial staging and high detection rate at re-staging. Future assessment of 124 I-MIBG PET for treatment guidance including personalized 131 I-MIBG therapy is warranted.

show abstract

The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer

Cited by 22 publications

References 84 publications

A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer

A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer

Intra-Individual Comparison of 124I-PET/CT and 124I-PET/MR Hybrid Imaging of Patients with Resected Differentiated Thyroid Carcinoma: Aspects of Attenuation Correction

Diagnostic Performance of ¹²⁴I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma

Contact Info

Product

Resources

About

The role of 124I PET/CT lesion dosimetry in differentiated thyroid cancer

Cited by 22 publications

References 84 publications

A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer

A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer

Intra-Individual Comparison of 124I-PET/CT and 124I-PET/MR Hybrid Imaging of Patients with Resected Differentiated Thyroid Carcinoma: Aspects of Attenuation Correction

Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma

Contact Info

Product

Resources

About

Diagnostic Performance of ¹²⁴I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma